Business
Agenus Expands Executive Leadership Team
Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie
About this update from Agenus Inc.
[{"type":"text","content":"\nRobin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer\n\n\nHoma Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer\n\n\nStephanie Fagan Appointed Chief Communications Officer\n\n\n LEXINGTON, Mass.--(BUSINESS WIRE)--\nImmuno-oncology leader, Agenus Inc. (“Agenus”) (Nasdaq: AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company’s next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics.\n\n\nChief Commercial Officer, Robin Taylor, Ph.D., is an accomplished leader with demonstrated success in global commercial development in oncology. His expertise in commercialization strategies, market access, and product launches will accelerate Agenus’ growth and ultimately enable the delivery of the company’s therapies to patients as the company evolves to a multi-product organization.\n\n\nChief Product Strategy and Global Medical Affairs Officer, Homa Yeganegi, brings expertise in medical affairs and a passion for advancing patient care. Her success in building and leading global medical affairs teams will play a pivotal role in deepening physicians’ understanding of the transformational potential of botensilimab. By fostering strong relationships with the medical community, she will contribute to the development and future commercialization of the company’s immuno-oncology programs.\n\n\nChief Communications Officer, Stephanie Fagan, brings extensive experience working with leading healthcare companies and executing successful communication, investor relations and advocacy strategies. Her proven record in building strong brands and engaging stakeholders will shape Agenus’ communication efforts and drive patient-centered initiatives to enhance the potential role of botensilimab in the treatment of cancer.\n\n\n\"We are at an incredibly exciting juncture in our company's history, with a portfolio of promising therapies showing significant clinical activity across a range of hard-to-treat cancers in patients who have not responded to previous therapies,\" said Chairman and Chief Executive Officer Garo Armen, Ph.D. \"With the...